Karyopharm Therapeutics

Update in progress

KPTI (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Karyopharm Therapeutics is a commercial-stage biopharma focused on drugs that block nuclear export to treat cancer. It develops Selective Inhibitors of Nuclear Export (SINE) targeting exportin 1 (XPO1). Its lead product selinexor (XPOVIO) is studied in multiple myeloma and DLBCL. It also works on eltanexor and KPT-9274, and partners with Menarini, Antengene, FORUS, and BMS. Headquartered in Newton, MA, since 2008.

Company score

Sentiment: 0.24; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.17; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.08; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.07; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.15; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive

Company

MarketNasdaqGS (NMS)
LocationUnited States
CEOMr. Richard A. Paulson M.B.A.
Founded2008
Employees228
Websitewww.karyopharm.com

Identifiers

ISINUS48576U2050
FIGIBBG001J272L7
CUSIP48576U106
CIK0001503802